Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for PBH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 1.018B
March 31, 2026 -38.10M
December 31, 2025 -6.732M
September 30, 2025 -74.95M
June 30, 2025 -36.28M
March 31, 2025 -11.49M
December 31, 2024 -53.86M
September 30, 2024 -51.20M
June 30, 2024 -65.52M
March 31, 2024 -68.44M
December 31, 2023 -64.84M
September 30, 2023 -53.55M
June 30, 2023 -54.18M
March 31, 2023 -80.50M
December 31, 2022 -10.02M
September 30, 2022 -47.96M
June 30, 2022 -47.37M
March 31, 2022 -54.12M
December 31, 2021 -67.64M
September 30, 2021 50.53M
June 30, 2021 63.65M
March 31, 2021 -83.71M
December 31, 2020 -9.044M
September 30, 2020 -75.30M
June 30, 2020 -111.36M
Date Value
March 31, 2020 20.56M
December 31, 2019 -55.68M
September 30, 2019 -47.02M
June 30, 2019 -49.29M
March 31, 2019 -45.00M
December 31, 2018 -53.10M
September 30, 2018 -99.85M
June 30, 2018 -51.38M
March 31, 2018 -64.35M
December 31, 2017 -40.00M
September 30, 2017 -54.02M
June 30, 2017 -50.59M
March 31, 2017 774.55M
December 31, 2016 -65.02M
September 30, 2016 -100.24M
June 30, 2016 -47.44M
March 31, 2016 167.54M
December 31, 2015 -25.90M
September 30, 2015 -44.72M
June 30, 2015 -42.89M
March 31, 2015 -49.82M
December 31, 2014 -54.13M
September 30, 2014 711.16M
June 30, 2014 36.06M
March 31, 2014 -96.70M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Indivior Pharmaceuticals, Inc. -172.64M
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M
Veru, Inc. -0.0519M
Johnson & Johnson -8.777B